ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
Rhea-AI Summary
ProMIS Neurosciences (Nasdaq: PMN) announced that CEO Neil Warma will speak at the 8th Annual Evercore Healthcare Conference on December 2, 2025. The appearance includes a fireside chat at 3:25 PM ET and investor one-on-one meetings.
A live webcast of the presentation will be available via the company Events page at www.promisneurosciences.com and will remain accessible for at least 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PMN gained 3.55%, reflecting a moderate positive market reaction. Argus tracked a peak move of +9.4% during that session. Argus tracked a trough of -12.5% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $587K to the company's valuation, bringing the market cap to $17M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum data flags a broader biotech move, with peers like PASG and XCUR down 13.06% and 4.13%. Other high-affinity peers show mixed single‑day moves between about -3.93% and +4.33%, suggesting stock-specific and sector influences both in play.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Scientific publication | Positive | +12.0% | Peer-reviewed data on selective toxic Aβ oligomer targeting and ARIA risk. |
| Dec 01 | Scientific publication | Positive | +3.5% | Plasma pTau analysis supporting biomarker endpoints in Alzheimer’s trials. |
| Dec 01 | Conference participation | Neutral | +3.5% | Announcement of CEO fireside chat and 1x1 meetings at Evercore event. |
| Nov 24 | Reverse stock split | Negative | -22.4% | One-for-twenty-five reverse split to address Nasdaq bid-price deficiency. |
| Nov 12 | Earnings & update | Neutral | +4.0% | Q3 2025 results with higher R&D spend and PRECISE-AD trial progress. |
Recent fundamental and scientific updates have generally seen positive single-day price reactions, while capital structure actions like the reverse split triggered a pronounced selloff.
Over the last few months, ProMIS has combined financial restructuring with steady clinical and scientific messaging. A one-for-twenty-five reverse split on Nov 28, 2025 coincided with a sharp negative move, while Q3 2025 results, PRECISE-AD enrollment progress, and two Alzheimer’s-related peer‑reviewed publications in December 2025 all drew modestly positive reactions. Today’s conference participation fits a pattern of active investor engagement alongside ongoing PMN310 development.
Regulatory & Risk Context
An effective S-3 shelf filed on Sep 4, 2025 provides the company with pre-cleared flexibility to issue various securities over time, subject to effectiveness and market conditions. The prospectus emphasizes liquidity and going-concern risks, past reverse splits, and other corporate actions, underscoring ongoing financing and regulatory considerations for shareholders.
Market Pulse Summary
This announcement highlights ProMIS’s participation in a high‑visibility healthcare conference, featuring a CEO fireside chat and webcast archived for at least 30 days. It follows recent Alzheimer’s‑focused publications, Q3 2025 results, and a one-for-twenty-five reverse split. Investors may track how management frames trial timelines, liquidity needs described in recent filings, and potential use of the S‑3 shelf when evaluating the company’s strategic and funding path.
AI-generated analysis. Not financial advice.
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will be participating in a fireside chat and investor one-on-one meetings at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd, 2025.
The fireside chat will be held at 3:25pm Eastern Time and a live webcast of the presentation may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com. The webcast will be available for at least 30 days following the event.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
About PMN310 and the PRECISE-AD Trial for Alzheimer’s Disease (AD)
PMN310, the Company’s lead product candidate for the treatment of AD, is a humanized monoclonal antibody that has been designed to selectively target only the toxic oligomers, avoiding plaque, thereby potentially reducing or eliminating amyloid-related imaging abnormalities (ARIA) liability. In addition, because PMN310 may not be limited by off-target binding or side effects, PMN310 could potentially offer an improved efficacy profile over other amyloid-directed antibody therapeutics. PMN310 was granted Fast Track designation by the U.S. Food and Drug Administration in July 2025.
Based on the encouraging results from the Phase 1a trial (NCT06105528) of PMN310, ProMIS initiated PRECISE-AD, a Phase 1b clinical trial in AD patients. PRECISE-AD (NCT06750432) is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple ascending doses (5, 10, 20 mg/kg) of intravenous PMN310 in patients with Mild Cognitive Impairment due to AD and mild AD (Stage 3 and Stage 4 AD). PRECISE-AD will be the first study to examine the effects of a monoclonal antibody directed solely against AβO on biomarkers associated with AD pathology and clinical outcomes. Safety will be a primary outcome of the study with particular emphasis on assessing whether, as a non-plaque binder, PMN310 may have a reduced risk of ARIA. The study is powered to provide
EpiSelectTM Drug Discovery Engine
Toxic misfolded proteins underlie the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Generation of therapeutic antibodies selectively targeting only disease-misfolded protein isoforms, while sparing normal or irrelevant isoforms of the same protein, has not yet been successfully achieved by conventional immunization strategies. ProMIS Neurosciences has developed a computational platform (EpiSelectTM) to identify conformational epitopes that are uniquely exposed on toxic misfolded proteins, which can then be used to generate misfolding-specific antibodies or vaccine formulations. Application of the ProMIS platform produced PMN310, a clinical stage, humanized monoclonal antibody candidate that has been shown to be highly selective for toxic amyloid-beta oligomers (AβO) without significant reactivity with amyloid-beta monomers or fibrils, thereby avoiding target distraction by these more abundant species, and potentially reducing the risk of brain edema and microhemorrhages associated with the targeting of vascular/parenchymal amyloid. Similarly, specific epitopes for alpha-synuclein toxic oligomers/soluble fibrils that drive synucleinopathies, and for pathogenic TDP-43 in ALS and FTD have been identified and lead candidate antibodies generated. The precise conformation of these epitopes has been translated into vaccines inducing an antibody response selective for pathogenic molecular species in preclinical mouse vaccination studies.
For further information:
Visit us at www.promisneurosciences.com
Please submit media inquiries to info@promisneurosciences.com
For Investor Relations, please contact:
Kaytee Bock Zafereo
katherine.bock@promisneurosciences.com
FAQ
When will ProMIS Neurosciences CEO Neil Warma present at the Evercore Healthcare Conference (PMN)?
How can investors watch ProMIS Neurosciences (PMN) at the Evercore conference?
How long will the ProMIS Neurosciences Evercore webcast be available after the event?
What topics will ProMIS Neurosciences (PMN) cover during the Evercore fireside chat?
Will ProMIS Neurosciences (PMN) offer investor one-on-one meetings at the Evercore conference?
Where can I find the ProMIS Neurosciences webcast link for the Evercore Healthcare Conference?
